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Heart-lung transplantation has become an established treatment for end stage respiratory failure secondary to 
cystic fibrosis. The success of this form of treatment, and the increasing survival of such patients, suggests 
there will be an increased need for transplantation over the next decade. We have used cystic fibrosis 
population predictions and all cause mortality data to estimate the number of cardio-pulmonary deaths, due 
to cystic fibrosis, over the next decade and to estimate the number of such patients who are likely to benefit 
from heart-lung transplantation. We estimate that there will be between 85 and 127 potential transplant 
recipients with cystic fibrosis each year over the next decade. During 1990, 1991 and 1992 there were less than 
40 transplants each year in such patients. These data emphasize the need to expand transplantation services 
and to maintain the availability of donor organs. 
Introduction 
The prognosis for patients with cystic fibrosis has 
improved dramatically over the past three decades 
and many patients now survive into the third decade 
with a good quality of life (1,2). The majority of 
patients die as a result of respiratory failure often 
associated with car pulmonale. Heart-lung, and 
double lung, transplantation are now established 
treatments for end stage cardio-respiratory failure in 
patients with cystic fibrosis (CF) with over 100 trans- 
planted to date in the United Kingdom (3,4). The 
outlook following this procedure is good with 
approximately 50% survival for more than 3 years 
following this procedure (5). 
The availability of donor organs is limited and it is 
already clear that the demand for organs suitable for 
heart-lung transplantation is well in excess of supply 
(6,7), but the extent of the shortfall is not known. To 
establish the requirement for donor organs we have 
used mortality predictions for CF to estimate the 
number of such patients likely to benefit from heart- 
lung transplantation over the next decade in England 
and Wales. 
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Methods 
The size of the population of patients with CF was 
estimated as previously described (1). In brief, using a 
logistic model, survival for each year of birth cohort 
from 1959 to 2000 was extrapolated after adjusting 
for trends in the first year mortality. From this data 
life tables were constructed and estimates of the likely 
number of deaths by age until 2000 for individuals 
with CF were derived. 
We obtained multiple cause of death data from 
the Office of Population, Census and Surveys 
(OPCS) for the years 1985 and 1986, the only years 
for which it is available, to ascertain the likely 
proportion of deaths due to terminal pulmonary 
disease. Deaths registered as cardiac or respiratory 
failure were considered to be potential recipients of 
heart-lung transplantation. Patients with cause of 
death registered as due to liver disease, haemoptysis 
or other causes were considered as unlikely to 
benefit from heart-lung transplantation. 
These data were combined with the predicted 
number of deaths due to CF in order to estimate the 
number of patients who might benefit from heart- 
lung transplantation. We obtained the numbers of 
patients with CF who have received transplants 
in 1990, 1991 and 1992 and the total number of 
heart-lung and lung transplants for those years from 
the U.K. Transplant Support Services Authority, 
Southmead Road, Bristol BSlO 5NG. 
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Table 1 Predicted number of deaths per year in 5 year age bands for the next decade in England 
and Wales 
Age (years) 1990 91 92 93 94 95 96 97 98 99 2000 
G-5 
6-10 
11-15 
Total 
16-20 
21-25 
25 
Total 
10 10 9 8 8 7 5 5 5 3 3 
12 11 10 9 8 6 8 6 5 5 3 
24 26 25 26 25 17 16 15 12 12 10 
46 47 44 43 41 30 29 26 22 20 16 
26 20 23 21 21 32 35 36 30 33 32 
24 24 26 28 28 26 21 22 26 21 34 
39 29 23 26 31 34 35 45 46 52 53 
89 73 72 75 80 92 91 103 102 106 119 
Results 
The amalgamated numbers of deaths in five year 
age bands from 1990 to 2000 are shown in Table 1. 
Over the next decade the model predicts a fall in the 
number of deaths in those under 16 years from 46 to 
16 per annum and an increase in the number of 
deaths of patients with CF over the age of 16 years 
from 72 to 119 per annum. 
In the years 1985 and 1986, 257 deaths due to CF 
were reported in England and Wales. The causes of 
death mentioned in the death certificates are summar- 
ized in Table 2. Considering all patients with cause of 
death registered as cardiac or respiratory disease 
(73% of all deaths) to represent the proportion of 
potential transplant patients, between 85 and 99 
patients per year over the next decade will be poten- 
tial recipients of a transplant. If certificates recording 
CF, without mention of other causes, are also 
included (21% of all deaths) the potential number of 
patients requiring transplantation will be 109 to 127 
per year. In 1990, 60% of potential recipients were 
predicted to be aged greater than 16 years. In con- 
trast by the year 2000,85% of potential recipients will 
be over 16 years of age. 
Deaths registered due to liver disease (2%) or 
pulmonary haemorrhage (4%) were considered 
unlikely to benefit from heart-lung transplantation. 
A further five recorded deaths mentioned CF, but 
not as the underlying cause of death. Of these, three 
were due to perinatal infection and one to perinatal 
haemorrhage. One death was a homicide. 
In 1990 a total of 94 patients received heart-lung 
transplantation and 52 lung only, in 1991 74 had 
heart-lung transplant and 72 lung only and in 1992 
53 heart-lung and 89 lung only. The number of 
notified heart-lung and lung only transplants in 
patients with CF in 1990 was 29 heart-lung and 
seven lung only, in 1991 29 heart-lung and five lung 
only transplants and in 1992 19 heart-lung and 10 
lung only. 
Discussion 
This study demonstrates that the great majority of 
patients with CF die as a consequence of respiratory 
Table 2 Primary cause of death by age group for the years 1985 and 1986 in patients with cystic fibrosis. Figures in 
brackets are the percentages of total deaths for each age band 
Age (years) Respiratory Cardiac Hepatic Pulmonary haemorrhage CF only Other 
1 11 (69) 1 (16) 0 0 4 (25) 
14 10 (63) 2 (13) 0 0 
: 
(24) 0 
5-9 18 (53) 5 (15) 2 (6) 0 8 (23) 1 (3) 
10-14 29 (59) 5 (10) 2 (4) 2 (4) 11 (22) 0 
15-19 41 (62) 7 (11) 1 (2) 2 (3) 15 (23) 0 
2&24 22 (52) 7 (17) 1 (2) 3 (7) 9 (21) 0 
25-29 14 (58) 4 (17) 0 2 (8) 4 (17) 0 
30+ 6 (6’3) 3 (30) 0 0 1 (10) 0 
Total 151 (59) 34 (13) 6 (2) 9 (4) 52 (20) 5 (2) 
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failure often associated with cardiac failure. Deaths 
due to hepatic disease and pulmonary haemorrhage 
only occurred during the second and third decades of 
life in patients with CF. Although the absolute 
numbers are small there is no suggestion that either is 
becoming more common with increasing survival. 
The study suggests that the requirement for trans- 
plantation in CF patients will amount to between 85 
and 127 per year. Some patients may not wish to 
have such a procedure, or will be unsuitable for other 
reasons, and so it is likely that the lower figure of this 
range is the most reasonable estimate. During 1990, 
199 1 and 1992 less than 40 patients were transplanted 
and this includes patients from Scotland, Northern 
Ireland and Europe, which have not been included in 
our estimates of potential recipients suffering from 
CF which only account for deaths in England and 
Wales. 
The main factor limiting heart-lung transplan- 
tation is the availability of donor organs (6). Recent 
independent estimates suggest that 150-200 donor 
organs, suitable for lung, or heart-lung, transplan- 
tation, are available each year in the U.K. (personal 
communication; Dr P. A. Corris). During 1990, 1991 
and 1992, 146, 151 and 142 transplants were carried 
out respectively, suggesting that the majority of 
potentially available organs are currently being fully 
utilized. Major efforts need to be made to improve 
this situation but it is unlikely that enough human 
organs will be available to meet the potential needs 
of patients with chronic cardiopulmonary disease 
who might benefit from transplantation (6,7). Other 
possible approaches, such as using animal xenograft 
transplantation, need to be considered as alternatives 
if the need is to be met. 
Patients with CF represent the largest single 
group of current recipients and it is clear that if 
present levels of transplantation continue, less than 
one third of patients will benefit from the procedure 
due to the limited availability of donor organs. 
Transplant centres have reported that 3@40% of 
patients on their waiting lists die (8,9). If current 
levels of transplantation continue, and further 
patients are added to waiting lists, this figure is 
likely to increase (8). There are contra-indications 
to transplantation in patients with CF but, as 
experience of the procedure increases, many of these 
may be regarded as relative rather than absolute 
(5,9). However, considering the limited availability 
of donor organs, it is important that patient selec- 
tion criteria are applied which result in the best 
outcome for those undergoing transplantation. This 
will present many difficulties as for the majority of 
patients with CF, suitable transplantation will be in 
their, potentially, most productive years of life. 
Many such patients are dying while on a waiting list 
for transplantation and this is likely to have a 
psychological impact on those considering referral 
for transplantation. In addition there may be press- 
ure on referring physicians to send patients earlier 
in the course of their disease for assessment which 
might further inflate the waiting list numbers. 
Few children will require transplantation over the 
next decade and so resources will need to be pri- 
marily directed towards the requirements of adults. It 
is evident that the great majority of deaths from CF, 
and consequently the burden of morbidity will occur 
in individuals over the age of 16 years. Adequate 
facilities for the care of these patients will need to be 
developed, as suggested by the recent report on the 
care of adult patients with CF by the Royal College 
of Physicians of London (3,lO). 
This study shows that the potential requirements 
for organs for heart-lung transplantation will be 
very much greater than available supplies for 
patients with CF over the next decade. This empha- 
sizes the need for new treatments for the pulmonary 
disease due to CF in order to preserve lung function 
for as long as possible (11). It is unlikely that 
human allograft transplantation will ever meet the 
potential needs and other options, such as animal 
organ transplantation, need to be explored. Every 
effort must continue to be made to maximize the 
availability of human organs for patients with 
chronic cardio-pulmonary disease. 
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